Alnylam reports positive results from ILLUMINATE-B phase 3 study of Lumasiran

This article was originally published here

ILLUMINATE-B is now the seventh Phase 3 study of an RNAi therapeutic that has yielded positive results, and the first-ever study evaluating the safety and efficacy of this

The post Alnylam reports positive results from ILLUMINATE-B phase 3 study of Lumasiran appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply